Efficacy and Safety of Statins in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.
Adv TherJul 18, 2026 (epub)
Han Deng, Ran Wang, Yuhang Yin et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of statins in patients with liver cirrhosis, analyzing data from thirteen randomized controlled trials. The study found that statins significantly reduced overall mortality (RR 0.63, 95% CI 0.47-0.84) and hepatic venous pressure gradient (MD 0.96, 95% CI 0.35-1.57), while also decreasing the incidence of spontaneous bacterial peritonitis.
Key findings
- Statins significantly decreased overall mortality (RR 0.63, 95% CI 0.47-0.84).
- Statins reduced hepatic venous pressure gradient (MD 0.96, 95% CI 0.35-1.57).
- Statins increased the proportion of patients achieving HVPG response (RR 1.88, 95% CI 1.04-3.38).
- Statins significantly reduced the incidence of spontaneous bacterial peritonitis (RR 0.35, 95% CI 0.16-0.75).
Why it matters
The findings suggest that statins may offer a therapeutic benefit in reducing mortality and complications associated with liver cirrhosis, which is crucial given the high morbidity and mortality rates in this population.